stoxline Quote Chart Rank Option Currency Glossary
  
Biofrontera Inc. (BFRI)
1.18  0.01 (0.85%)    02-14 16:00
Open: 1.19
High: 1.19
Volume: 217,379
  
Pre. Close: 1.17
Low: 1.11
Market Cap: 10(M)
Technical analysis
2025-02-14 4:46:36 PM
Short term     
Mid term     
Targets 6-month :  1.44 1-year :  1.69
Resists First :  1.23 Second :  1.44
Pivot price 1.11
Supports First :  1.07 Second :  0.97
MAs MA(5) :  1.13 MA(20) :  1.1
MA(100) :  1.01 MA(250) :  1.14
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  62.5 D(3) :  53.7
RSI RSI(14): 59.6
52-week High :  2.43 Low :  0.65
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BFRI ] has closed below upper band by 12.0%. Bollinger Bands are 55.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.19 - 1.2 1.2 - 1.2
Low: 1.1 - 1.1 1.1 - 1.11
Close: 1.17 - 1.18 1.18 - 1.19
Company Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Headline News

Sun, 26 Jan 2025
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024 - ACCESS Newswire

Wed, 08 Jan 2025
Biofrontera Inc. Announces Achievement of Key Milestone In - GlobeNewswire

Wed, 11 Dec 2024
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga

Tue, 03 Dec 2024
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Yahoo Finance

Tue, 03 Dec 2024
Biofrontera to Present at Benchmark's Discovery Investor Conference in NYC - StockTitan

Fri, 22 Nov 2024
Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 9 (M)
Shares Float 3 (M)
Held by Insiders 32 (%)
Held by Institutions 20.6 (%)
Shares Short 457 (K)
Shares Short P.Month 201 (K)
Stock Financials
EPS 1.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.16
Profit Margin -38.4 %
Operating Margin -64.7 %
Return on Assets (ttm) -40.3 %
Return on Equity (ttm) -149.5 %
Qtrly Rev. Growth 34 %
Gross Profit (p.s.) 1.89
Sales Per Share 3.97
EBITDA (p.s.) -2.07
Qtrly Earnings Growth 0 %
Operating Cash Flow -19 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio 1.01
PEG Ratio 0
Price to Book value 0.37
Price to Sales 0.29
Price to Cash Flow -0.56
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android